In its first-quarter 2026 investor letter, Mairs & Power Balanced Fund highlighted stocks like Abbott Laboratories (NYSE:ABT).
Abbott Laboratories (NYSE:ABT) is a healthcare company that develops medical devices, diagnostics, nutrition products, and branded medicines
The one-month return of Abbott Laboratories (NYSE:ABT) was -1.03% while its shares traded between $81.97 and $139.06 over the last 52 weeks. On June 1, 2026, Abbott Laboratories (NYSE:ABT) stock closed at approximately $87.78 per share, with a market capitalization of about $152.25 billion. Mairs & Power Balanced Fund stated the following regarding Abbott Laboratories (NYSE:ABT) in its Q1 2026 investor letter: “Also, negatively impacting performance during the quarter was the Fund’s exposure to Health Care.
Abbott Laboratories (NYSE:ABT) impacted performance as guidance in the nutrition business flagged and growth decelerated elsewhere.” Abbott Laboratories (NYSE:ABT) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. As per our database, 73 hedge fund portfolios held Abbott Laboratories (NYSE:ABT) at the end of the fourth quarter, compared to 71 in the previous quarter. While we acknowledge the risk and potential of Abbott Laboratories (NYSE:ABT) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame.